Squawk Pod: NYC Shooting, US-China Trade Talks, and Sarepta Therapeutics Update

Midtown Manhattan Shooting and Corporate Security

• 💔 A gunman killed a New York City police officer and three civilians in a Midtown Manhattan office building, later dying by suicide.
• 🏢 The building housed offices for major companies including the NFL, Blackstone, and KPMG.
• 🧠 Investigators are exploring the suspect's note, which suggested a link between mental illness, football, and CTE.
• 🗣️ Security experts emphasize the need for intelligence-led security programs for early threat detection and rapid response.
• 🔒 Debates continue on hardening buildings and the role of armed security, with practicality and perception being key considerations.
• ⚖️ The incident also reignited discussions on mental illness and gun access, highlighting the complexities of gun control debates.

US-China Trade Negotiations

• 🇨🇳 Trade talks between the US and China in Stockholm have shown no clear indication of progress after two days.
• 🗣️ President Trump's tone shifted, downplaying the likelihood of an immediate summit with President Xi, possibly as a bargaining tactic.
• 📉 Expectations were low, with hopes primarily focused on extending the August 1st tariff deadline.
• 🇺🇸 The US seeks completely open markets from trading partners, aiming to rectify decades of perceived unfair trade policies.

US-EU Trade Deal and Pharmaceuticals

• 🇪🇺 Commerce Secretary Howard Lutnick hailed a new trade deal with the European Union as a significant victory for President Trump.
• 🚗 Key components of the deal include commitments on energy purchases and investments in America, alongside a 15% tariff on goods.
• 💊 The inclusion of pharmaceuticals was crucial, with the EU agreeing to a 15% tariff to preempt a potentially higher US pharmaceutical policy.
• 📈 The deal aims to address the US trade surplus with Europe and encourage onshoring of manufacturing.

Sarepta Therapeutics Gene Therapy Update

• 🚀 Sarepta Therapeutics will resume shipping its gene therapy, Elevus, to ambulatory patients after FDA scrutiny.
• ⚠️ The FDA had recommended a pause due to serious safety concerns following patient deaths, though one recent death was deemed unrelated to the therapy.
• 🤝 Sarepta is working with the FDA to update safety labels and discuss risk mitigation for non-ambulatory patients.
• 📉 Despite a pre-market jump, Sarepta shares remain significantly down for the year.